Supplement Claims for Pregnancy Symptoms: Confusion Reigns
Feb. 4, 2000 (Washington) -- While it may appear unusual, if not downright ridiculous, to define pregnancy as a disease or abnormal condition, a new FDA rule now has a number of experts imploring the federal agency to seriously consider adopting this definition.
The rule, scheduled to take effect Monday, would permit makers of dietary supplements to market their products for the treatment of morning sickness and fluid retention, two conditions that accompany many pregnancies. The rule basically is a result of the Dietary Supplement Health and Education Act of 1994 (DSHEA), which, when passed, was intended to ensure that consumers could receive adequate information about the effects of dietary supplements on the "structure or function" of their bodies. To facilitate the exchange of this information, the law permitted dietary supplement makers to make these claims without conducting the same clinical trials required of prescription drug makers.
The rule excludes any claims to treat a disease or its symptoms, at which point the product would be considered a prescription drug. But while the FDA historically has applied this exclusion to limit a large number of structure and function claims, last month the agency decided that common symptoms such as morning sickness are structure and function claims. The decision comes in response to a lawsuit that challenged -- based on First Amendment rights -- the FDA's previous limitations.
The agency's move has placed it in a difficult position. "Pregnancy is not a disease," says Jennifer Niebyl, MD, chairwoman of obstetrics and gynecology at the University of Iowa Medical School, in Iowa City. But there are conditions inherent to pregnancy that might affect complications [of the supplements]," she says. And these conditions, she tells WebMD, necessitate the testing of any product given to pregnant women for both safety and effectiveness.
Niebyl is not alone in this belief. "This current policy is an invitation for disaster," says Godfrey Oakley, MD, a professor of epidemiology at the Emory University School of Medicine, in Atlanta. "You shouldn't have a public policy that encourages pregnant women to take a substance that has not been tested for safety," he says. Both Oakley, who is a past director of the division of birth defects at the CDC, and Niebyl add that they have sent separate letters to the FDA stating exactly that.